

# Criteria-Based Consultation Prescribing Program

## CRITERIA FOR DRUG COVERAGE

### Estradiol acetate vaginal ring (Femring)

#### Notes:

- Quantity Limits: No

**Initiation (new start) criteria:** Non-formulary **estradiol acetate vaginal ring (Femring)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient has vasomotor symptoms of menopause severe enough to interfere with daily activities and/or sleep
- Patient has failed an adequate trial of the following unless an allergy, intolerance or regimen adherence issues.
  - Two estradiol transdermal patch products, such as a weekly patch (Climara and generics) and a biweekly patch (Vivelle Dot and generics) **-AND-**
  - Topical estradiol gel (Divigel and generics)
- If patient has an intact uterus then prescribed a progestogen, such as micronized progesterone (Prometrium and generics) or medroxyprogesterone acetate (Provera and generics), as a separate entity

**Criteria for current and new Kaiser Permanente members already taking the medication who have not been reviewed previously:** Non-formulary **estradiol acetate vaginal ring (Femring)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Vasomotor symptoms are partially or fully resolved
- If patient has an intact uterus then prescribed a progestogen, such as micronized progesterone (Prometrium and generics) or medroxyprogesterone acetate (Provera and generics), as a separate entity

**Continued use criteria for patients previously approved per the above criteria who are currently stable on the medication:** Non-formulary **estradiol acetate vaginal ring (Femring)** will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Vasomotor symptoms are partially or fully resolved
- Starting at 60 years of age: If symptoms have fully resolved, then trial off to determine if symptoms return and drug treatment is still medically necessary. Repeat a trial off every 2 years.
- If patient has an intact uterus then prescribed a progestogen, such as micronized progesterone (Prometrium and generics) or medroxyprogesterone acetate (Provera and generics), as a separate entity